Oman is exploring a comprehensive strategy to develop its pharmaceutical and medical devices industry, emphasizing the need for a targeted industrial policy backed by a robust incentive framework. Experts suggest that such an approach is essential to build a competitive local sector capable of attracting major investors, enhancing domestic capabilities, integrating into global value chains, and progressing toward higher-value activities.
International case studies from countries like Ireland, Costa Rica, and Singapore highlight the importance of tailored investment-promotion strategies. These nations have successfully cultivated pharmaceutical and medical-device clusters by identifying priority sectors, developing customized investment packages, and engaging with investors beyond initial establishment. For Oman, this model could be adapted to focus on pharmaceutical manufacturers, medical device producers, biotechnology firms, contract manufacturers, and companies with regional export potential.
A key recommendation involves linking incentives not merely to the establishment of production facilities but to measurable economic outcomes. Metrics such as investment size, quality and quantity of job creation, export performance, local procurement, technology transfer, training of Omani personnel, and research and development activities could form the basis for incentive eligibility. This would shift incentives from being purely cost-based government subsidies to strategic tools aimed at achieving specific industrial development objectives.
Post-investment support, or "investment aftercare," is also emphasized as critical for sustaining growth. Maintaining ongoing engagement through dedicated teams could help identify obstacles to expansion and encourage reinvestment. Firms that establish operations in Oman may be motivated to increase production, launch new products, develop regional export hubs, or establish research and technical centers through such support.
Another focus area is strengthening local supplier networks. Encouraging foreign companies to source more goods and services from qualified Omani suppliers, supported by supplier development programs, technical assistance, quality certifications, financing, and matchmaking initiatives, could bolster domestic industry without imposing rigid local-content requirements. A capability-based approach would incentivize multinationals to actively nurture Omani suppliers and facilitate knowledge and technology transfers.
Human capital development is regarded as essential, given the technical expertise required in pharmaceutical manufacturing. Collaboration between the government, investors, universities, and technical institutions could yield targeted training programs. Additionally, investors benefiting from incentives might be encouraged to implement structured skills transfer initiatives for Omani workers.
Research and development (R&D) forms a critical pillar of the proposed strategy, with Singapore cited as a successful example of moving industries up the value chain. Oman could introduce enhanced incentives for companies establishing R&D centers, clinical research units, testing laboratories, product development platforms, or regional technical facilities. These incentives would be tiered to reward higher-value activities such as R&D, exporting, local supplier development, and the employment of highly skilled Omanis.
Infrastructure development in key industrial zones like Salalah and Khazaen is also recognized as important. Specialized facilities— including testing laboratories, quality control units, cold-chain logistics, waste management systems, and training centers—should evolve in response to actual industrial demand rather than speculative construction.
Finally, government procurement policies could support nascent local manufacturers by providing an initial market, where quality, safety, and value-for-money criteria are met. Such procurement can help domestic producers achieve the scale and experience necessary to compete internationally.
Overall, the proposed multi-faceted approach aims to position Oman’s pharmaceutical industry as a competitive and sustainable sector integrated with global markets.